To the full analysis
Buyback calculator for Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine stock: key metrics
600276.SSJiangsu Hengrui Medicine had an operating margin of 25.5% and a return on invested capital (ROIC) of 33.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 81.3% | 20.4% | 14.5% |
| 2007 | 83.1% | 25.9% | 21.1% |
| 2008 | 83.2% | 18.8% | 17.7% |
| 2009 | 82.7% | 25.5% | 22.0% |
| 2010 | 83.8% | 22.6% | 19.3% |
| 2011 | 82.8% | 22.7% | 19.3% |
| 2012 | 83.9% | 23.6% | 19.8% |
| 2013 | 81.3% | 23.4% | 20.0% |
| 2014 | 82.3% | 23.8% | 20.3% |
| 2015 | 85.3% | 27.5% | 23.3% |
| 2016 | 87.1% | 27.3% | 23.3% |
| 2017 | 86.6% | 27.5% | 23.2% |
| 2018 | 86.6% | 26.4% | 23.3% |
| 2019 | 87.5% | 26.4% | 22.9% |
| 2020 | 87.9% | 25.3% | 22.8% |
| 2021 | 85.5% | 18.0% | 17.5% |
| 2022 | 83.5% | 19.3% | 18.4% |
| 2023 | 84.4% | 21.5% | 18.9% |
| 2024 | 86.1% | 26.8% | 22.6% |
| 2025 | 84.9% | 25.5% | 24.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 16.6% | 28.2% | 14.2% |
| 2007 | 25.6% | 52.6% | 20.5% |
| 2008 | 21.2% | 34.6% | 18.8% |
| 2009 | 25.5% | 38.9% | 22.2% |
| 2010 | 21.4% | 33.2% | 18.6% |
| 2011 | 20.8% | 30.6% | 18.2% |
| 2012 | 20.7% | 29.0% | 18.3% |
| 2013 | 19.5% | 29.4% | 17.1% |
| 2014 | 19.1% | 33.1% | 16.7% |
| 2015 | 21.9% | 44.0% | 18.9% |
| 2016 | 20.9% | 39.9% | 18.1% |
| 2017 | 20.9% | 33.0% | 17.8% |
| 2018 | 20.6% | 28.8% | 18.2% |
| 2019 | 21.5% | 38.1% | 19.3% |
| 2020 | 20.7% | 46.2% | 18.2% |
| 2021 | 12.9% | 28.3% | 11.5% |
| 2022 | 10.3% | 20.3% | 9.2% |
| 2023 | 10.6% | 21.3% | 9.8% |
| 2024 | 13.9% | 32.0% | 12.6% |
| 2025 | 12.6% | 33.3% | 11.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Strong
- Valuation signal Undervalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.